---
title: "Kissei Pharmaceutical's (TSE:4547) Solid Earnings May Rest On Weak Foundations"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286824222.md"
description: "Kissei Pharmaceutical's recent earnings appear solid, but concerns arise from a significant contribution of JP¥18b from unusual items, which may mislead investors about its underlying profitability. Despite a 45% growth in earnings per share over three years, analysts caution that statutory profits may not accurately reflect the company's true earnings power. Additionally, there are two warning signs to consider regarding the company's risks."
datetime: "2026-05-18T22:05:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286824222.md)
  - [en](https://longbridge.com/en/news/286824222.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286824222.md)
---

# Kissei Pharmaceutical's (TSE:4547) Solid Earnings May Rest On Weak Foundations

The recent earnings posted by **Kissei Pharmaceutical Co., Ltd.** (TSE:4547) were solid, but the stock didn't move as much as we expected. We believe that shareholders have noticed some concerning factors beyond the statutory profit numbers.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

TSE:4547 Earnings and Revenue History May 18th 2026

## The Impact Of Unusual Items On Profit

For anyone who wants to understand Kissei Pharmaceutical's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from JP¥18b worth of unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often **not** repeated the next year. Which is hardly surprising, given the name. Kissei Pharmaceutical had a rather significant contribution from unusual items relative to its profit to March 2026. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

## Our Take On Kissei Pharmaceutical's Profit Performance

As we discussed above, we think the significant positive unusual item makes Kissei Pharmaceutical's earnings a poor guide to its underlying profitability. For this reason, we think that Kissei Pharmaceutical's statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. Nonetheless, it's still worth noting that its earnings per share have grown at 45% over the last three years. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. If you'd like to know more about Kissei Pharmaceutical as a business, it's important to be aware of any risks it's facing. For example - Kissei Pharmaceutical has **2 warning signs** we think you should be aware of.

This note has only looked at a single factor that sheds light on the nature of Kissei Pharmaceutical's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this **free** collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

### Valuation is complex, but we're here to simplify it.

Discover if Kissei Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring **fair value estimates, potential risks, dividends, insider trades, and its financial condition.**

Access Free Analysis

### Related Stocks

- [4547.JP](https://longbridge.com/en/quote/4547.JP.md)

## Related News & Research

- [ADVISORY-Incorrectly tagged Kissei alert withdrawn](https://longbridge.com/en/news/286617469.md)
- [Amgen Japanese Partner Urges Caution On Tavneos Use](https://longbridge.com/en/news/286794592.md)
- [Dyno Nobel's (ASX:DNL) Performance Is Even Better Than Its Earnings Suggest](https://longbridge.com/en/news/286962011.md)
- [We Think That There Are Issues Underlying DAIHEN's (TSE:6622) Earnings](https://longbridge.com/en/news/286824193.md)
- [Nippon Ceramic's (TSE:6929) Solid Profits Have Weak Fundamentals](https://longbridge.com/en/news/286657915.md)